Use Nepadutant in a sentence

1. Nepadutant (INN) (code name MEN-11420) is a glycosylated bicyclic cyclo hexapeptide drug which acts as a highly selective NK 2 receptor antagonist. It was developed by the Menarini Group and investigated for the treatment of functional gastrointestinal disorders and asthma but was never marketed.

Nepadutant, Name, Nk, Never

2. Nepadutant definition: Noun (uncountable) 1

Nepadutant, Noun

3. Menarini was developing oral Nepadutant, a potent and selective tachykinin neurokinin-2 receptor antagonist, for the treatment of infant colic.

Nepadutant, Neurokinin

4. English Wikipedia has an article on: Nepadutant

Nepadutant

5. Nepadutant is postulated to have a therapeutic effect in infant colic since it reverts exaggerated intestinal motility and sensitivity induced by different stimuli through the activation of neurokinin-2 receptors, without interferring on the on physiological gastrointestinal transit.

Nepadutant, Neurokinin

6. In animal models, Nepadutant reverse the exaggerated intestinal motility and sensitivity, induced by different stimuli, without producing inhibitory effects on these functions at baseline, suggesting that Nepadutant could have a therapeutic effect with no interference on physiological gastrointestinal transit.

Nepadutant, No

7. Nepadutant did not affect blood pressure and heart rate up to 10 μmol/kg, whereas saredutant (SR 48968 or ((S)- N -methyl- N [4- (4-acetylamino-4-phenyl piperidino)-2- (3,4-dichlorophenyl)butyl] benzamide), a nonpeptide antagonist, produced a transient reduction of mean blood pressure and heart rate.

Nepadutant, Not, Nonpeptide

8. The effect of the tachykinin NK2 receptor antagonist, Nepadutant (MEN 11420 or (c{[(β-d-GlcNAc)Asn–Asp–Trp–Phe–Dpr–Leu]c(2β–5β)})) was assessed on car…

Nepadutant

9. Description Nepadutant has been used in trials studying the treatment of Colic, Infantile Colic, and Infantile Functional Gastrointestinal Disorders.

Nepadutant

10. Nepadutant did not affect blood pressure and heart rate up to 10 micromol/kg, whereas saredutant (SR 48968 or ((S)-N-methyl-N[4-(4-acetylamino-4-phenyl piperidino)-2-(3,4-dichlorophenyl)butyl

Nepadutant, Not

11. Nepadutant tpgs pharmaceutical composition aqueous composition Prior art date 2012-07-12 Application number PCT/IB2013/055754 Other languages French (fr) Inventor Claudia LEWERENZ Reinhard Schmitz Maria Altamura Original Assignee Laboratori Guidotti S.P.A

Nepadutant, Number

12. This compound has since been joined by many other nonpeptide compounds such as SR-144190 (Sanofi), GR-159897 (Glaxo), YM-38336 (Yamanouchi) and SB-414240 (SmithKlineBeecham) and by cyclic peptide-based compounds such as MEN-11420/Nepadutant (Menarini).

Nonpeptide, Nepadutant

13. Nepadutant ([N 4 -(2-acetamido-2-deoxy-b-D-glucopyranosyl)-L- asparaginyl-L-aspartyl-L-tryptophyl-L-phenylalanyl-L-2,3-diamino- propionyl-L-leucyl]-C-4.2-N-3.5-lactam-C-1.6-N-2.1-lactam), is a

Nepadutant

14. Nepadutant pharmacokinetics and dose-effect relationships as tachykinin NK2 receptor antagonist are altered by intestinal inflammation in rodent models

Nepadutant

15. A single administration of Nepadutant (0.3-10 mg/kg s.c., 1 h before acetic acid) markedly reduced the macroscopic damage and necrosis score and the increase in plasma protein extravasation induced by 7.5% acetic acid in the early phase of the injury.

Nepadutant, Necrosis

16. Nepadutant (INN) (code name MEN-11420) is a glycosylated bicyclic cyclo hexapeptide drug which acts as a highly selective NK 2 receptor antagonist. It was developed by the Menarini Group and investigated for the treatment of functional gastrointestinal disorders and asthma but was never marketed.

Nepadutant, Name, Nk, Never

17. MEN 11420 (Nepadutant), a novel glycosylated bicyclic peptide tachykinin NK2 receptor antagonist Br J Pharmacol

Nepadutant, Novel

18. Among these compounds, Nepadutant, a peptide-based antagonist, and saredutant, a nonpeptide antagoni st, are certainly among the most potent compounds

Nepadutant, Nonpeptide

19. 183747-35-5 - NGCNKEZHGRXHNL-WVWQGFTISA-N - Nepadutant [INN] - Similar structures search, synonyms, formulas, resource links, and other chemical information.

Ngcnkezhgrxhnl, Nepadutant

20. Accordingly, we investigated the effect of a selective neurokinin (NK) 2 receptor antagonist, Nepadutant, on proto-oncogene expression in the L6-S1 spinal cord as well as in dorsal root ganglion (DRG) neurons after either non-noxious colorectal distension (CRD) or

Neurokinin, Nk, Nepadutant, Neurons, Non, Noxious

21. Nepadutant; Saredutant; Talnetant; Overview

Nepadutant

22. Nepadutant is postulated to have a therapeutic effect in infant colic since it reverts exaggerated intestinal motility and sensitivity induced by different stimuli through the activation of neurokinin-2 receptors, without interferring on the on physiological gastrointestinal transit

Nepadutant, Neurokinin

23. The pharmacokinetics of MEN 11420 [Nepadutant, c[[(β-D-GlcNAc)Asn-Asp-Trp-Phe-Dpr-Leu]c(2β-5β)]], a potent glycosylated analogue of the selective, bicyclic peptide, tachykinin NK2 receptor antagonist MEN 10627 [c[(Met-Asp-Trp-Phe-Dpr-Leu)c(2β-5β)]], were studied in rats after different routes of administration

Nepadutant

24. MEN 11420 (Nepadutant), a novel glycosylated bicyclic peptide tachykinin NK 2 receptor antagonist R‐M Catalioto Department of Pharmacology, Menarini Ricerche S.p.A, …

Nepadutant, Novel, Nk

25. A new series of monocyclic pseudopeptidic tachykinin NK-2 receptor antagonists has been derived from Nepadutant with the help of site-directed mutagenesis studies and QSAR models

New, Nk, Nepadutant

26. Objectives: Nepadutant is a potent antagonist of tachykinin NK2 receptors found to control the gastrointestinal hypermotility

Nepadutant

27. In NIC-03, a phase IIa multicentre, randomised, double-blind, placebo controlled trial to study the efficacy of two oral Nepadutant doses (0.1 or 0.5 mg/kg) in infants with colic, a population Exposure-Response (ER

Nic, Nepadutant

28. Nepadutant (8 mg i.v.), a selective NK2 receptor antagonist, antagonised small intestine motility induced by NKA and prevented associated intestinal adverse events.

Nepadutant, Nka

29. The intrarectal (i.r.) administration of Nepadutant (100 nmol/kg) did not reduce [βAla 8]NKA(4-10) (10 nmol/kg i.v.)-induced colonic and bladder contractions in normal animals, but the same dose of Nepadutant produced an inhibitory effect in the two organs following rectocolitis; in contrast, Nepadutant is equieffective by the intravenous

Nepadutant, Nmol, Not, Nka, Normal

30. Defacto, Nepadutant is currently in phase II clinical trials and was selected as refer-ence compound for further developments

Nepadutant

31. Nepadutant is a glycosylated analogue of the potent, selec-tive, conformationally constrained NK2 receptor antagonist MEN10627 (cyclo{(Met-Asp-Trp-Phe-Dpr-Leu) cyclo(2L-5L)}) [6,7].

Nepadutant

32. Abstract: Objectives: Nepadutant is a potent antagonist of tachykinin NK2 receptors found to control the gastrointestinal hypermotility

Nepadutant

33. In NIC-03, a phase IIa multicentre, randomised, double-blind, placebo controlled trial to study the efficacy of two oral Nepadutant doses (0.1 or 0.5 mg/kg) in infants with colic, a population Exposure-Response (ER) analysis was performed.

Nic, Nepadutant

34. A new series of monocyclic pseudopeptidic tachykinin NK-2 receptor antagonists has been derived from Nepadutant with the help of site-directed mutagenesis studies and QSAR models

New, Nk, Nepadutant

35. Maggi, Effect of Nepadutant, a Neurokinin 2 Tachykinin Receptor Antagonist, on Immediate-Early Gene Expression after Trinitrobenzenesulfonic Acid-Induced Colitis in the Rat, Journal of Pharmacology and Experimental Therapeutics, 10.1124/jpet.102.042077, 304, 1, (272

Nepadutant, Neurokinin

36. MEN 11420 (Nepadutant), a novel glycosylated bicyclic peptide tachykinin NK 2 receptor antagonist

Nepadutant, Novel, Nk

37. The purpose of the study is to evaluate the gastrointestinal absorption of Nepadutant after single dose as oral solution (and the effect of age on its oral absorption) in infants

Nepadutant

38. MEN 11420 (Nepadutant), a novel glycosylated bicyclic peptide tachykinin NK 2 receptor antagonist

Nepadutant, Novel, Nk

39. MEN11420 (Nepadutant) is a bicyclic peptide tachykinin NK 2 receptor antagonist

Nepadutant, Nk

40. The aim of the trial was to examine the effect of Nepadutant on neurokinin A-induced bronchoconstriction in man

Nepadutant, Neurokinin

41. Disclosed is the use of a tachykinin antagonist for preparing pharmaceutical formulations for paediatric use for treating infantile colics, wherein said formulations are in a suitable form for oral administration, and wherein the tachykinin antagonist is a NK2 antagonist chosen from: cyclo((Asn (beta-D-2-deoxy-2-acetamido-Glc)-Asp-Trp-Phe-Dap-Leu)cyclo(2beta-5beta)), (Nepadutant) cyclo((Asn

Nepadutant

42. Among others, Nepadutant and ibodutant are two NK 2 R-antagonists that have shown promising clinical implications, such as reduced gut motility and pain

Nepadutant, Nk

43. Antagonist, Nepadutant,9 reduced contraction fre-quency and amplitude on migrating motor complexes in the small intestine in healthy controls

Nepadutant

44. Nepadutant, however did not reduce the number of preparations with high amplitude colonic contractions (from 12 to 10 out of 12)

Nepadutant, Not, Number

45. Atropine and Nepadutant (but not hexamethonium) also reduced the resting tone of acid-treated colons, however only the effect of …

Nepadutant, Not

46. Introduction Nepadutant is a potent antagonist of tachykinin NK2 receptors found to control the gastrointestinal hypermotility, tested in clinical phase IIa studies

Nepadutant

47. In NIC-03, a phase IIa multicentre, randomised, double-blind, placebo controlled to study the efficacy of two oral Nepadutant doses (0.1 or 0.5mg/kg) in colicky infants, a

Nic, Nepadutant